Why the study?
Underrepresented patients with pulmonary arterial hypertension may face worse outcomes, and whether genetic mechanisms in pathogenesis impact minority populations remains incompletely understood.
Understanding health disparities and genetic factors in minority populations with PAH is essential for improving care and advancing personalized medicine.
Disparities may worsen PAH outcomes in minorities; leaves open whether genetic insights apply equitably across ancestries.
Health disparities have a major impact in the quality of life and level of clinical care received in minority populations in the United States. Underrepresented patients with pulmonary arterial hypertension (PAH) may be at risk for worse outcomes. Furthermore, advances in biomedical research have provided extensive knowledge on the genetic role in the pathogenesis of PAH but whether these also impact minorities is incompletely understood. Health disparities in patients with PAH create an enormous barrier in health care delivery. Understanding the contributors to health disparity represent a fundamental step towards personalized medicine and further improvement in PAH care.
No takes yet. Share an insight, caveat, or question.
A 2022 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: